Search the site

Nasal Delivery of Haemophilus haemolyticus Is Safe, Reduces Influenza Severity, and Prevents Development of Otitis Media in Mice

Despite vaccination, influenza and otitis media (OM) remain leading causes of illness. We previously found that the human respiratory commensal Haemophilus haemolyticus prevents bacterial infection in vitro and that the related murine commensal Muribacter muris delays OM development in mice. The observation that M muris pretreatment reduced lung influenza titer and inflammation suggests that these bacteria could be exploited for protection against influenza/OM.

Identifying pediatric lung disease: A comparison of forced oscillation technique outcomes

These findings suggest the utility of specific FOT outcomes is dependent on the respiratory disease being assessed

Evaluation of a bacterial therapy for prevention of respiratory infection including influenza and otitis media

Deborah Lea-Ann Peter Ruth Strickland Kirkham Richmond Thornton PhD PhD MBBS MRCP(UK) FRACP PhD Head, Pregnancy and Early Life Immunology Co-Head,

PAEDS - Paediatric Active Enhanced Surveillance

The PAEDS Study monitors childhood conditions of public health importance that are difficult to effectively capture through other surveillance mechanisms.

Group mindful self-compassion training to improve mental health outcomes for gender and sexually diverse young adults

This study investigated the effects of Mindful Self-Compassion (MSC) training on the mental health of gender and sexually diverse young adults (aged 18–25 years) in Australia. A single-blind randomized controlled trial was conducted in 2020–2022 comparing an online-delivered 8-week group MSC training program with a waitlist control.

Nasal delivery of a commensal Pasteurellaceae species inhibits nontypeable Haemophilus influenzae colonisation and delays onset of otitis media in mice

We have demonstrated that a single dose of a closely related commensal can delay onset of NTHi otitis media in vivo

Promising results for new Western Australian-pioneered cystic fibrosis drug

Children with cystic fibrosis will be included in the next phase of a clinical trial of a promising new treatment pioneered in Western Australia aimed at boosting their immune responses to infections. Originally developed by researchers at The Kids Research Institute Australia and Perth Children’s Hospital.

Mind The Distance

Yael Penelope Keely Bep Amy Helen Perry Strauss Bebbington Uink Finlay-Jones Milroy BPsych (Hons) MPsych (Clin) PhD BA, MPH, PhD MClinPsych/PhD

Impact: Paradigm Shift

On this Research Impact page, we showcase real game-changers - research that changes the very way other scientists around the world think and approach challenges. The far-reaching impact on children and families for all the stories shown on these pages is both exciting and significant.

Publications

Browse the published work of the Centre's researchers